Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced the ...

IMMvention retained rights to use its technology to potentially pursue other targets, such as Parkinson’s or Alzheimer’s ...

Emory Moore, a 12-year-old treated at Brenner Children’s Hospital for sickle cell disease, received a special day with the Wake Forest basketball team. Despite her diagnosis, which prevents her from ...

Since two groundbreaking treatments were approved in late 2023, only a handful of patients have been able to access the ...

Dr. Joseph Lubega calls sickle cell disease “probably the saddest story of a health problem that you could imagine.” He and ...

Rigel Pharmaceuticals has enrolled the first subject in a Phase I trial of its oral spleen tyrosine kinase (SYK) inhibitor, ...

A groundbreaking study reveals that individuals with sickle cell disease show premature brain aging, appearing 14 years older ...

Statistics from the district health department indicate that in 2023, suspected cases of sickle cells stood at 1,456 and in ...

Novo Nordisk is opening a new front in its fight against sickle cell disease, inking a deal with IMMvention Therapeutix to co ...

The CDC states that, on average, sickle cell disease reduces a patient's lifespan by more than 20 years, which is why Carla ...

IMMvention and Novo Nordisk form a partnership to co-develop oral therapies for sickle cell disease, focusing on BACH1 ...

IMMvention Therapeutix, Inc ., an early-stage biotechnology company focused on discovering and developing human therapeutics, today announced a strategic collaboration and license agreement with Novo ...